HRP20140252T1 - Derivati imidazola kao inhibitori kazeinske kinaze - Google Patents
Derivati imidazola kao inhibitori kazeinske kinaze Download PDFInfo
- Publication number
- HRP20140252T1 HRP20140252T1 HRP20140252AT HRP20140252T HRP20140252T1 HR P20140252 T1 HRP20140252 T1 HR P20140252T1 HR P20140252A T HRP20140252A T HR P20140252AT HR P20140252 T HRP20140252 T HR P20140252T HR P20140252 T1 HRP20140252 T1 HR P20140252T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- imidazol
- pyrimidin
- piperidin
- acceptable salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Spoj formule I:
[image]
,
ili njegove farmaceutski prihvatljive soli, naznačen time što:
A je 4- do 7-eročlani heterocikloalkil koji sadrži dušik, ili alternativno A može biti izravno kondenziran s prstenom na kojeg je vezan preko R1;
L je C1-3alkil;
R1 je vodik, C1-3alkil ili C3-4alkil;
svaki R2 je neovisno C1-3alkil, fluor, hidroksil, C1-3alkoksi ili cijano;
R3 je vodik, C1-3-alkil ili C3-4-alkil;
R4 je 5- do 10-eročlani heteroaril s 1 do 3 heteroatoma, izborno supstituiran s 1 do 3 supstituenta R7;
R5 je vodik ili -N(R8)2;
R6 je vodik, halogen ili C1-3alkil;
svaki R7 je neovisno halogen, -(CH2)t-F, C1-3alkil, -CF3, -(CH2)t-C3-4alkil, -(CH2)t-O-C1-3-alkil, -(CH2)t-cijano ili -(CH2)t-hidroksi;
Z je N ili -CR9;
svaki R8 je neovisno vodik ili C1-3-alkil;
R9 je vodik, C1-3alkil ili halogen;
m je 0, 1 ili 2;
n je 0, 1 ili 2;
t je 0, 1 ili 2.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegove farmaceutski prihvatljive soli, naznačen time što je A 4- do 7-eročlani heterocikloalkil koji sadrži dušik, i
[image]
je vezan na N u prstenu;
L je C1alkil;
svaki R2 je neovisno C1-3alkil ili fluor;
svaki R7 je neovisno halogen, -(CH2)t-F, C1-3alkil, -CF3, -(CH2)t-C3-4alkil ili -(CH2)t-O-C1-3alkil.
3. Spoj u skladu s patentnim zahtjevom 2, ili njegove farmaceutski prihvatljive soli, naznačen time što je A 5-eročlani heterocikloalkil koji sadrži dušik
gdje je navedeni heterocikloalkil pirolidin, i
[image]
je vezan na N u prstenu pirolidina, a m je nula.
4. Spoj u skladu s patentnim zahtjevom 2, ili njegove farmaceutski prihvatljive soli, naznačen time što je A 6-eročlani heterocikloalkil koji sadrži dušik
gdje je navedeni heterocikloalkil piperidin, i
[image]
je vezan na N u prstenu piperidina, a m je nula.
5. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegove farmaceutski prihvatljive soli, naznačen time što je n 1, a R7 je fluor.
6. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegove farmaceutski prihvatljive soli, naznačen time što je Z N, a R5 je -N(R8)2, gdje je svaki R8 vodik.
7. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegove farmaceutski prihvatljive soli, naznačen time što je R1 vodik ili C1-3alkil.
8. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegove farmaceutski prihvatljive soli, naznačen time što R4 je 5-eročlani heteroaril, gdje je navedeni heteroaril izoksazol, izborno supstituiran s 1 ili 2 supstituenta R7, a t je nula.
9. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegove farmaceutski prihvatljive soli, naznačen time što je R3 vodik ili C1-3alkil.
10. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između:
4-{4-(4-fluorfenil)-1-[1-(pirimidin-2-ilmetil)piperidin-4-il]-1H-imidazol-5-il}pirimidin-2-amina;
4-{4-(4-fluorfenil)-1-[1-(izoksazol-3-ilmetil)piperidin-4-il]-1H-imidazol-5-il}pirimidin-2-amina;
4-{4-(4-fluorfenil)-1-[1-(izoksazol-3-ilmetil)piperidin-4-il]-1H-imidazol-5-il}-N-metilpirimidin-2-amina;
4-{4-(4-fluorfenil)-1-[1-(izoksazol-3-ilmetil)piperidin-4-il]-1H-imidazol-5-il}pirimidina;
4-{4-(4-fluorfenil)-1-[1-(izoksazol-3-ilmetil)pirolidin-3-il]-1H-imidazol-5-il}pirimidin-2-amina;
2-{[4-(4-fenil-5-pirimidin-4-il-1H-imidazol-1-il)piperidin-1-il]metil}pirimidina;
N-metil-4-{4-fenil-1-[1-(pirimidin-2-ilmetil)piperidin-4-il]-1H-imidazol-5-il}pirimidin-2-amina;
4-{1-[1-(izoksazol-3-ilmetil)piperidin-4-il]-4-fenil-1H-imidazol-5-il}pirimidin-2-amina;
4-{1-[1-(izoksazol-3-ilmetil)piperidin-4-il]-4-fenil-1H-imidazol-5-il}-N-metilpirimidin-2-amina;
4-{4-(4-fluorfenil)-1-[1-(1,3-tiazol-5-ilmetil)piperidin-4-il]-1H-imidazol-5-il}pirimidin-2-amina;
4-[4-(4-fluorfenil)-1-{1-[(2-metilpiridin-4-il)metil]piperidin-4-il}-1H-imidazol-5-il]pirimidin-2-amina;
i
4-{4-(4-fluorfenil)-1-[1-(piridazin-4-ilmetil)piperidin-4-il]-1H-imidazol-5-il}pirimidin-2-amina;
4-[4-(4-fluorfenil)-1-{1-[(2-metilpirimidin-5-il)metil]piperidin-4-il}-1H-imidazol-5-il]pirimidin-2-amina,
ili njihovih farmaceutski prihvatljivih soli.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-10, ili njegove farmaceutski prihvatljive soli, naznačen time što je namijenjen upotrebi u inhibiranju aktivnosti CK1 delta ili CK1 epsilon kod pacijenta.
12. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, ili njegove farmaceutski prihvatljive soli, naznačen time što navedeno inhibiranje aktivnosti CK1 delta ili CK1 epsilon rezultira produljenjem perioda dnevnog ritma.
13. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-10, ili njegove farmaceutski prihvatljive soli, naznačen time što je namijenjen upotrebi u liječenju neurološke i psihijatrijske bolesti ili poremećaja.
14. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 13, ili njegove farmaceutski prihvatljive soli, naznačen time što navedena bolest ili poremećaj jest poremećaj raspoloženja ili poremećaj spavanja.
15. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 14, ili njegove farmaceutski prihvatljive soli, naznačen time što se poremećaj raspoloženja bira iz skupine koju čine depresivni poremećaj i bipolarni poremećaj.
16. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivu podlogu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25550609P | 2009-10-28 | 2009-10-28 | |
| PCT/IB2010/054749 WO2011051858A1 (en) | 2009-10-28 | 2010-10-20 | Imidazole derivatives as casein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140252T1 true HRP20140252T1 (hr) | 2014-04-25 |
Family
ID=43301770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140252AT HRP20140252T1 (hr) | 2009-10-28 | 2010-10-20 | Derivati imidazola kao inhibitori kazeinske kinaze |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8518944B2 (hr) |
| EP (1) | EP2493876B1 (hr) |
| JP (1) | JP5784620B2 (hr) |
| KR (1) | KR101421852B1 (hr) |
| CN (1) | CN102686580B (hr) |
| AR (1) | AR078797A1 (hr) |
| AU (1) | AU2010311035B2 (hr) |
| CA (1) | CA2777632C (hr) |
| DK (1) | DK2493876T3 (hr) |
| ES (1) | ES2460065T3 (hr) |
| HR (1) | HRP20140252T1 (hr) |
| IL (1) | IL219190A0 (hr) |
| IN (1) | IN2012DN03182A (hr) |
| MX (1) | MX2012004997A (hr) |
| PL (1) | PL2493876T3 (hr) |
| PT (1) | PT2493876E (hr) |
| RS (1) | RS53246B (hr) |
| SI (1) | SI2493876T1 (hr) |
| TW (1) | TW201125864A (hr) |
| UY (1) | UY32977A (hr) |
| WO (1) | WO2011051858A1 (hr) |
| ZA (1) | ZA201202776B (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2669693C (en) | 2006-11-15 | 2018-06-12 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| RS59098B1 (sr) * | 2010-12-20 | 2019-09-30 | Pfizer | Nova fuzionisana piridin jedinjenja kao inhibitori kazein kinaze |
| US20150209367A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| EP2935271B1 (en) | 2012-12-21 | 2017-10-25 | Bristol-Myers Squibb Company | Novel substituted imidazoles as casein kinase 1 / inhibitors |
| US9732065B2 (en) | 2013-05-30 | 2017-08-15 | Sumitomo Dainippon Pharma Co., Ltd. | Cyclic aminomethyl pyrimidine derivative |
| ES2926931T3 (es) | 2014-02-07 | 2022-10-31 | Agency Science Tech & Res | Inhibidores de caseína quinasa 1 basados en azoles 2,4,5-tri-sustituidos como inductores de la cardiomiogénesis |
| US20170314027A1 (en) | 2014-08-06 | 2017-11-02 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| EP3273955A4 (en) | 2015-03-23 | 2019-05-01 | The University of Melbourne | TREATMENT OF RESPIRATORY DISEASES |
| US11185536B2 (en) * | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| EP3407901B1 (en) | 2016-01-29 | 2021-07-21 | Massachusetts Eye & Ear Infirmary | Expansion and differentiation of inner ear supporting cells and methods of use thereof |
| WO2018201192A1 (en) * | 2017-05-03 | 2018-11-08 | The University Of Melbourne | Compounds for the treatment of respiratory diseases |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| CA3111848A1 (en) * | 2018-09-09 | 2020-03-12 | Qanatpharma Ag | Use of casein kinase 1 inhibitors for treating vascular diseases |
| WO2020093097A1 (en) | 2018-11-07 | 2020-05-14 | The University Of Melbourne | Compounds and compositions for the treatment of respiratory diseases |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
| CN115298183A (zh) * | 2020-03-27 | 2022-11-04 | 北京原基华毅生物科技有限公司 | 作为酪蛋白激酶抑制剂的化合物 |
| AR122711A1 (es) * | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992012154A1 (en) * | 1990-12-31 | 1992-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Imidazotriazine derivatives |
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| EP0889888A4 (en) * | 1996-03-25 | 2003-01-08 | Smithkline Beecham Corp | NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM |
| US6239279B1 (en) | 1998-12-16 | 2001-05-29 | Smithkline Beecham Corporation | Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives |
| GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| AU2002316279B2 (en) * | 2001-06-18 | 2007-08-23 | The Rockefeller University | Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| PT1747220E (pt) * | 2003-12-11 | 2009-07-08 | Aventis Pharma Inc | 1h-pirrolo[3,2-b, 3,2-c e 2,3-c]piridina-2-carboxamidas e análogos relacionados como inibidores da caseína-cinase i epsilon |
| JO2629B1 (en) * | 2004-08-19 | 2012-06-24 | افينتيس فارما سوتيكالز انك | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon |
| CA2577511A1 (en) * | 2004-08-19 | 2006-03-02 | Aventis Pharmaceuticals Inc. | 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase ie |
| JP5119157B2 (ja) * | 2005-10-21 | 2013-01-16 | エクセリクシス， インク． | カゼインキナーゼｉｉ（ｃｋ２）モジュレーターとしてのピラゾロ−ピリミジン類 |
| EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| RS59098B1 (sr) | 2010-12-20 | 2019-09-30 | Pfizer | Nova fuzionisana piridin jedinjenja kao inhibitori kazein kinaze |
-
2010
- 2010-10-20 DK DK10774282.7T patent/DK2493876T3/en active
- 2010-10-20 KR KR1020127013537A patent/KR101421852B1/ko not_active Expired - Fee Related
- 2010-10-20 EP EP10774282.7A patent/EP2493876B1/en active Active
- 2010-10-20 RS RS20140157A patent/RS53246B/en unknown
- 2010-10-20 AU AU2010311035A patent/AU2010311035B2/en not_active Ceased
- 2010-10-20 CN CN201080059759.7A patent/CN102686580B/zh not_active Expired - Fee Related
- 2010-10-20 MX MX2012004997A patent/MX2012004997A/es active IP Right Grant
- 2010-10-20 CA CA2777632A patent/CA2777632C/en not_active Expired - Fee Related
- 2010-10-20 PL PL10774282T patent/PL2493876T3/pl unknown
- 2010-10-20 SI SI201030539T patent/SI2493876T1/sl unknown
- 2010-10-20 HR HRP20140252AT patent/HRP20140252T1/hr unknown
- 2010-10-20 PT PT107742827T patent/PT2493876E/pt unknown
- 2010-10-20 ES ES10774282.7T patent/ES2460065T3/es active Active
- 2010-10-20 JP JP2012535977A patent/JP5784620B2/ja active Active
- 2010-10-20 IN IN3182DEN2012 patent/IN2012DN03182A/en unknown
- 2010-10-20 WO PCT/IB2010/054749 patent/WO2011051858A1/en active Application Filing
- 2010-10-25 TW TW099136328A patent/TW201125864A/zh unknown
- 2010-10-25 US US12/911,030 patent/US8518944B2/en active Active
- 2010-10-27 UY UY0001032977A patent/UY32977A/es not_active Application Discontinuation
- 2010-10-28 AR ARP100103948A patent/AR078797A1/es not_active Application Discontinuation
-
2012
- 2012-04-15 IL IL219190A patent/IL219190A0/en unknown
- 2012-04-16 ZA ZA2012/02776A patent/ZA201202776B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110098272A1 (en) | 2011-04-28 |
| KR101421852B1 (ko) | 2014-07-22 |
| EP2493876B1 (en) | 2014-02-12 |
| JP5784620B2 (ja) | 2015-09-24 |
| SI2493876T1 (sl) | 2014-04-30 |
| EP2493876A1 (en) | 2012-09-05 |
| ZA201202776B (en) | 2013-06-26 |
| WO2011051858A1 (en) | 2011-05-05 |
| DK2493876T3 (en) | 2014-03-10 |
| PL2493876T3 (pl) | 2014-06-30 |
| CA2777632A1 (en) | 2011-05-05 |
| UY32977A (es) | 2011-05-31 |
| TW201125864A (en) | 2011-08-01 |
| AU2010311035B2 (en) | 2013-05-16 |
| JP2013509392A (ja) | 2013-03-14 |
| AR078797A1 (es) | 2011-12-07 |
| PT2493876E (pt) | 2014-03-20 |
| RS53246B (en) | 2014-08-29 |
| CA2777632C (en) | 2014-02-25 |
| AU2010311035A1 (en) | 2012-05-03 |
| US8518944B2 (en) | 2013-08-27 |
| HK1171220A1 (en) | 2013-03-22 |
| CN102686580A (zh) | 2012-09-19 |
| IL219190A0 (en) | 2012-06-28 |
| KR20120088759A (ko) | 2012-08-08 |
| CN102686580B (zh) | 2014-09-10 |
| ES2460065T3 (es) | 2014-05-13 |
| IN2012DN03182A (hr) | 2015-09-25 |
| MX2012004997A (es) | 2012-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140252T1 (hr) | Derivati imidazola kao inhibitori kazeinske kinaze | |
| NO20084832L (no) | Pyrimidinderivater som P13K-inhibitorer | |
| JP2018502877A5 (hr) | ||
| KR101671341B1 (ko) | 다이아미노피리미딘 유도체 및 그의 제조방법 | |
| JP2009510086A5 (hr) | ||
| JP2006500348A5 (hr) | ||
| RU2007118538A (ru) | Производные хинолина | |
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| RU2000128036A (ru) | Амидиновые соединения | |
| HRP20100522T1 (hr) | Piridin karboksamidi kao inhibitori 11-beta-hsd1 | |
| RU2010138577A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3 | |
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| KR910009705A (ko) | 수용성이 개선된 이미다조[4,5-b] 퀴놀리닐 옥시알칸산 아미드 | |
| RU2010116821A (ru) | N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr | |
| HRP20110882T1 (hr) | Ciklopenta [d] pirimidini kao inhibitori kinaze akt proteina | |
| RU2005122932A (ru) | Производные бензазепина для лечения неврологических нарушений | |
| CA2587642A1 (en) | Substituted heterocycles and methods of use | |
| NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
| JP2019520412A5 (hr) | ||
| JP2008525498A5 (hr) | ||
| MX2013010140A (es) | Amino-quinolinas como inhibidores de cinasa. | |
| JPWO2021055744A5 (hr) | ||
| PE20110807A1 (es) | Inhibidores de cinasa akt y p70 s6 | |
| JP2008540626A5 (hr) | ||
| RU2010129078A (ru) | Производные циклопропиламина |